Long-term use of atypical antipsychotics in bipolar disorder

Pharmacotherapy

Volumn 26, Issue 8 I, 2006, Pages 1134-1147

  Ehret, Megan J ^a   Levin, Gary M ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Bipolar disorder; Maintenance therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE; FLUOXETINE; LACTATE DEHYDROGENASE; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; VALPROIC ACID; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BIPOLAR DISORDER; BRADYCARDIA; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIZZINESS; DOPAMINE RELEASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; MEDICAL SOCIETY; MEMORY DISORDER; NAUSEA; PANCREATITIS; PATIENT COMPLIANCE; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PROPHYLAXIS; PSYCHOSIS; RECURRENT DISEASE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREMOR; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; PIPERAZINES; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; THIAZOLES; UNITED STATES;

EID: 33746727670     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8.1134     Document Type: Review

References (69)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association, 2000.
2. Weissman MM, Myers JK. Affective disorders in a U.S. urban community: the use of research diagnostic criteria in an epidemiological survey. Arch Gen Psychiatry 1978;35:1304-11.
3. Oliver JM, Simmons ME. Affective disorders and depression as measured by the diagnostic interview schedule and the Beck depression inventory in an unselected adult population. J Clin Psychol 1985;41:469-77.
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 1990;264:2511-18.
5. Weissman MM, Livingston BM, Leaf PJ, Florio LP, Holzer C. Affective disorders. In: Robins LN, Regier DA, eds. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, 1991:53-80.
6. Stefansson JG, Lindal E, Bjornsson JK, Guomundsdottir A. Lifetime prevalence of specific mental disorders among people born in Iceland in 1931. Acta Psychiatr Scand 1991;84:142-9.
7. Cassano GB, Dell'Osso L, Frank E, et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999;54:319-28.
8. Heun R, Maier W. The distinction of bipolar II disorder from bipolar I and recurrent unipolar depression: results of a controlled family study. Acta Psychiatr Scand 1993;87:279-84.
9. Szadoczky E, Papp Z, Vitrai J, Rihmer Z, Furedi J. The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998;50:153-62.
10. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50:143-51.
11. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the U.S. population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-31.
12. Goodwill FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990.
13. Goldberg JF, Harron M, eds. Bipolar disorders: clinical course and outcome. Washington, DC: American Psychiatric Press, 1999.
14. Frances A, Docherty JP, Kahn DA. The expert consensus guidelines series: treatment of bipolar disorder. J Clin Psych 1996;57(suppl 12):1-89.
15. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psych 2002;159(suppl 4):1-50.
16. Strakowski S, McElroy S, Keck P. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery S, eds. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000:143-57.
17. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999;100:406-17.
18. Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psych 1998;59(suppl 6):13-19.
19. Calabrese JR, Woyshville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psych 1995;7:103-12.
20. Soares JC. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol 2000;15:183-96.
21. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatments and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psych 1999;60(suppl 2):77-84.
22. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote mania study group. JAMA 1994;271:918-24.
23. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-66.
24. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomized study. J Affect Disord 1997;43:151-61.
25. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psych 2003;60:392-400.
26. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. J Clin Psych 2003;64:1013-24.
27. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
28. Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psych 2000;61(suppl 13):19-25.
29. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology Washington, DC: American Psychiatric Press Inc., 1997.
30. Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996;71:778-86.
31. Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994;8:211-33.
32. Fuller MA, Sajatovic M. Drug information handbook for psychiatry, 5th ed. Hudson: Lexi-Comp, 2005.
33. Strakowski SM, DelBello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001;15:701-18.
34. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997;31:393-432.
35. Yatham LN, Liddle PF, Dennie J, et al. Disease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psych 1999;178:705-11.
36. 2 receptors: a PET study Br J Psych 2001;178:448-53.
37. 2A receptors in depression: an {18F} setoperone PET imaging study. Am J Psych 2001;158:78-85.
38. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third-generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psych 2002;63:275-83.
39. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(suppl 2):S106-15.
40. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psych 2001;62:273-81.
41. Tohen M, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Poster presentation at the 156th annual meeting of the American Psychiatric Association, San Francisco, California, May 17-22, 2003.
42. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psych 2005;162:1281-90.
43. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psych 2003;160:1263-71.
44. Vieta E, Castro C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001;67:213-19.
45. Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol Clin Exp 2004;19:41-5.
46. Altamura AC, Salvadori D, Madaro D, Santini A, Mundo E. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76:267-71.
47. Warrington L, Keck PE, Potkin S, Loebel A, Giller E, Batzar E. Efficacy and safety of ziprasidone in bipolar disorder: long-term data. Poster presentation at the 44th annual meeting of the New Clinical Drug Evaluation Unit (National Institute of Mental Health), Phoenix, Arizona, June 1-4, 2004.
48. Keck P, Sanchez R, Marcus R, et al. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial. Poster presentation at the 157th annual meeting of the American Psychiatric Association, New York, NY, May 1-6, 2004.
49. Eli Lilly and Company. Symbyax (olanzapine-fluoxetine) product information. Indianapolis, IN; 2005.
50. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psych 2005;66(suppl 3):28-36.
51. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
52. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003;5(suppl 2):62-79.
53. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psych 2002;63(suppl 3):15-20.
54. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psych 2004;65(suppl 7):4-18.
55. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
56. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psych 2004;65:696-701.
57. Hirsch SR, Kissling W, Bauml J, Power A, O'Conner R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psych 2002;63:516-23.
58. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 2004;18:367-76.
59. Sanchez J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-80.
60. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26.
61. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9.
62. Petty R. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35(suppl):S67-73.
63. McIntyre RS, Mancini DA, Seinivasan J, et al. The antidepressant effects of risperidone and olanzapine in bipolar depression [online exclusive article]. Can J Clin Pharmacol 2004;11:e218-26. Available from http://www.cjcp.ca/pdf/ cjcp03-0015F_e218.pdf.
64. Keck PE. Evaluation and management of breakthrough depressive episodes. J Clin Psych 2004;65(suppl 10):11-15.
65. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;167:1351-60.
66. Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psych 2004;65:1537-45.
67. Murray L, ed. 2004 drug topics red book. Montvale, NJ: Thompson PDR, 2004.
68. Centers for Medicare and Medicaid Services. Available from www.cms.hhs.gov/clinicallabfeesched/02_clinlab.asp#TopofPage. Accessed May 31, 2006.
69. Begley CE, Annegers JF, Swann AC, et al. The lifetime costs of bipolar disorder in the U.S.: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-95.